83061-21-6Relevant articles and documents
Species differences in microsomal oxidation and glucuronidation of 4-ipomeanol: Relationship to target organ toxicity
Parkinson, Oliver T.,Teitelbaum, Aaron M.,Whittington, Dale,Kelly, Edward J.,Rettie, Allan E.
, p. 1598 - 1602 (2016)
4-Ipomeanol (IPO) is amodel pulmonary toxicant that undergoes P450-mediated metabolism to reactive electrophilic intermediates that bind to tissuemacromolecules and can be trapped in vitro as the NAC/NAL adduct. Pronounced species and tissue differences in IPO toxicity are well documented, as is the enzymological component of phase I bioactivation. However, IPO also undergoes phase II glucuronidation, which may compete with bioactivation in target tissues. To better understand the organ toxicity of IPO, we synthesized IPO-glucuronide and developed a new quantitative mass spectrometry-based assay for IPO glucuronidation. Microsomal rates of glucuronidation and P450-dependent NAC/NAL adduct formation were compared in lung, kidney, and liver microsomes from seven species with different target organ toxicities to IPO. Bioactivation rates were highest in pulmonary and renal microsomes from all animal species (except dog) known to be highly susceptible to the extrahepatic toxicities induced by IPO. In a complementary fashion, pulmonary and renal IPO glucuronidation rates were uniformly low in all experimental animals and primates, but hepatic glucuronidation rates were high, as expected. Therefore, with the exception of the dog, the balance between microsomal NAC/NAL adduct and glucuronide formation correlate well with the risk for IPO-induced pulmonary, renal, and hepatic toxicities across species.
